Complete Guide to Phase 0 (Microdosing Studies) in Clinical Trials

Phase 0, or microdosing studies, represents an innovative strategy in early drug development. Designed to expedite the drug evaluation process, Phase 0 trials involve administering extremely low doses of investigational compounds to human volunteers to gather early pharmacokinetic and pharmacodynamic data. This phase enables smarter decision-making before committing to full-scale Phase I studies.

Introduction to Phase 0 (Microdosing Studies)

Traditional clinical development often faces delays due to the high rate of failures in early-stage trials. Phase 0 studies emerged as a response, offering a faster and cost-effective means of assessing drug behavior in humans. These trials use microdoses that are far below therapeutic levels, ensuring minimal risk while providing valuable data to guide subsequent clinical phases.

What are Phase 0 (Microdosing Studies)?

Phase 0 clinical trials, also known as exploratory Investigational New Drug (eIND) studies, involve administering subtherapeutic doses of a drug to a small number of participants. The goal is not to assess safety or efficacy but to understand pharmacokinetics, pharmacodynamics, and early human bioavailability. These trials help sponsors determine whether to proceed with full development programs.

Key Components / Types of Phase 0 Studies

• Pharmacokinetic Studies: Focused on absorption, distribution, metabolism, and excretion (ADME) profiles.
• Pharmacodynamic Studies: Examining the biological response at very low drug concentrations.
• Bioavailability and Biodistribution Assessments: Using imaging or blood sampling to study how a drug moves through the body.
• Microdosing Techniques: Administering doses less than 1/100th of the dose calculated to yield a pharmacological effect.
• Exploratory IND Studies: Special regulatory pathways that facilitate quick approval for Phase 0 trials.

How Phase 0 Studies Work (Step-by-Step Guide)

1. Candidate Selection: Choosing molecules with strong preclinical data but uncertain human applicability.
2. Regulatory Approval: Submitting an exploratory IND application to obtain permission for Phase 0 testing.
3. Study Design: Planning pharmacokinetic or pharmacodynamic evaluations with microdoses.
4. Volunteer Recruitment: Enrolling 10–15 healthy participants or patients, depending on the drug profile.
5. Dosing and Monitoring: Administering single or repeated microdoses under strict clinical supervision.
6. Data Collection: Using advanced analytical methods like LC-MS/MS for ultra-sensitive drug concentration measurements.
7. Decision Making: Deciding whether to proceed, modify, or terminate development based on Phase 0 results.

Advantages and Disadvantages of Phase 0 Studies

Advantages:

• Accelerates early human data acquisition, saving time and resources.
• Identifies unsuitable drug candidates before expensive Phase I trials.
• Minimizes patient risk due to ultra-low dosing.
• Facilitates go/no-go decisions based on real human pharmacokinetics.

Disadvantages:

• Cannot provide comprehensive safety or efficacy data.
• Limited to drugs with measurable biomarkers at low concentrations.
• Regulatory pathways may vary across regions, adding complexity.
• Additional costs if Phase 0 does not result in clear conclusions.

Common Mistakes and How to Avoid Them

• Inadequate Analytical Sensitivity: Use validated ultra-sensitive assays to detect microdose concentrations.
• Poor Candidate Selection: Choose compounds with strong in vitro and in vivo support before entering humans.
• Failure to Engage Regulators: Discuss Phase 0 plans early with regulatory agencies to align expectations.
• Unclear Study Endpoints: Define clear, measurable objectives before trial initiation.
• Neglecting Ethical Considerations: Ensure informed consent clearly explains the non-therapeutic nature of Phase 0 studies.

Best Practices for Phase 0 Studies

• Exploratory IND Submission: Utilize regulatory pathways that expedite early-phase approvals.
• Robust Study Designs: Incorporate crossover designs and advanced imaging techniques to maximize data from small samples.
• Cross-functional Collaboration: Engage clinical pharmacologists, statisticians, and analytical chemists early in planning.
• Patient Engagement: Maintain transparency with participants regarding the study’s goals and limitations.
• Leverage Translational Biomarkers: Use biomarkers to bridge preclinical findings with human outcomes.

Real-World Example or Case Study

Case Study: Microdosing of Oncology Compounds

Several oncology drugs, including MEK inhibitors, have successfully used Phase 0 studies to evaluate human pharmacokinetics early. In one instance, microdosing revealed unfavorable metabolism profiles, prompting discontinuation and saving millions in Phase I development costs. This showcases the critical decision-making value of Phase 0 data.

Comparison Table: Phase 0 vs. Phase I Clinical Trials

Frequently Asked Questions (FAQs)

Is Phase 0 mandatory for drug development?

No, Phase 0 is optional and is typically used for exploratory purposes to inform early development decisions.

What regulatory approvals are needed for Phase 0 trials?

An Exploratory Investigational New Drug (eIND) application must be submitted to regulatory agencies like the FDA.

Are Phase 0 studies ethically acceptable?

Yes, provided that risks are minimized and participants give fully informed consent.

How are microdoses administered?

Microdoses are typically administered orally or intravenously under tightly controlled clinical conditions.

Can Phase 0 results be used to skip Phase I trials?

No, Phase 0 data complements but does not replace the need for Phase I safety and tolerability assessments.

Conclusion and Final Thoughts

Phase 0 (Microdosing Studies) introduces an intelligent, risk-mitigating step in early clinical development. By enabling early human data acquisition, these studies help sponsors make informed decisions about the future of drug candidates while minimizing ethical and financial risks. As clinical research continues to evolve, Phase 0 approaches will play a greater role in streamlining drug development pipelines. For more expert resources on clinical trials and innovative study designs, visit clinicalstudies.in.

Understanding Phase 0 Trials: Purpose, Design, and Why They Matter

What are Phase 0 Clinical Trials?

Phase 0 trials, also known as microdosing studies, are the earliest phase of human clinical research. Introduced as part of an exploratory IND (Investigational New Drug) framework by the U.S. FDA, Phase 0 studies are designed to collect preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data in humans using very low doses of investigational drugs.

Unlike traditional Phase 1–3 trials, Phase 0 trials do not aim to assess safety or efficacy. Instead, they serve as a critical go/no-go checkpoint that helps developers make faster and better-informed decisions.

Why Do Phase 0 Trials Exist?

Drug development is costly and time-consuming. Many candidates fail during Phase 1 or 2, resulting in major financial loss. Phase 0 trials provide a low-risk way to:

• Screen multiple drug candidates quickly
• Understand human pharmacokinetics before full-scale trials
• Reduce overall R&D costs by filtering out poor candidates early
• Test target engagement or mechanism of action using biomarkers

In essence, Phase 0 studies enhance efficiency in drug development pipelines, especially for oncology, CNS, and biologic therapies.

Primary Objectives of Phase 0 Trials

Phase 0 studies are designed to address specific scientific questions, such as:

• Does the drug reach the intended tissue or site of action?
• Is the drug absorbed and metabolized as expected in humans?
• Can target engagement be confirmed at a microdose level?
• Should further development be pursued or abandoned?

These insights are critical for early decision-making and derisking the drug development process.

What is a Microdose?

A microdose is defined by regulatory agencies as:

• 1/100th of the pharmacologically active dose, or
• Not more than 100 micrograms for small molecules

At such low levels, the drug is not expected to produce a therapeutic or toxic effect, making it safer for administration to healthy volunteers or select patient populations.

Design and Structure of Phase 0 Trials

1. Sample Size

Phase 0 trials typically include 6–15 subjects. The small sample size is adequate for early PK/PD measurements and feasibility testing.

2. Duration

These studies are short, often lasting just 1–7 days, depending on the drug’s half-life and endpoint collection timelines.

3. Study Population

• Healthy volunteers are usually enrolled
• Cancer patients may be enrolled in oncology-targeted Phase 0 studies

4. Dosing and Route of Administration

The drug is administered via the intended clinical route—oral, IV, inhalation, etc.—but at microdose levels. Serial sampling is conducted to capture plasma, urine, or tissue levels.

5. Endpoint Measurements

• Pharmacokinetics (Cmax, AUC, half-life)
• Pharmacodynamics (biomarker changes)
• Tissue penetration or receptor binding (e.g., using PET imaging)

Regulatory Framework: Phase 0 and the FDA

The U.S. FDA first formalized Phase 0 trials under its Exploratory IND guidance (2006). This allowed sponsors to begin human trials with:

• Reduced animal toxicology requirements
• Limited preclinical data (e.g., single-dose tox in one species)
• Shorter timelines and lower costs

Other regulatory bodies like EMA, CDSCO, and PMDA have also acknowledged microdosing studies under their respective risk-based frameworks.

Advantages of Conducting a Phase 0 Study

• Speeds up development by providing early human data
• Allows comparison of multiple drug candidates
• Supports rational decision-making with limited investment
• Reduces failure rates in later clinical phases

Limitations and Considerations

Despite the advantages, Phase 0 studies have limitations:

• Microdose PK may not extrapolate to therapeutic doses
• No safety or efficacy evaluation is performed
• Not all drugs are suitable for microdosing (e.g., nonlinear kinetics)

Therefore, careful candidate selection and predictive modeling (e.g., PBPK) are essential.

Real-World Example

An oncology company evaluated two small-molecule inhibitors using Phase 0 design. Volunteers received microdoses of both drugs, and plasma PK and PET imaging were used to assess tumor uptake. One drug showed high tissue penetration; the other did not. Based on Phase 0 data, the company progressed only the promising candidate to Phase 1, saving millions in development costs.

Summary for Clinical Research Students

Phase 0 trials represent a paradigm shift in drug development—small, focused, data-driven studies that provide early human insight. As a student or aspiring clinical researcher, understanding the objectives and structure of Phase 0 trials prepares you to contribute meaningfully to early-phase program design and regulatory strategy.

They are not replacements for Phase 1 studies but rather an exploratory tool to streamline discovery and development while minimizing risk and cost.

A Step-by-Step Guide to Designing a Microdosing Study for Phase 0 Trials

What is a Microdosing Study?

A microdosing study involves the administration of extremely low, sub-therapeutic doses of a drug to human subjects to evaluate early pharmacokinetic (PK) and pharmacodynamic (PD) behavior. These studies fall under the category of Phase 0 clinical trials and are designed to provide rapid, human-specific data with minimal risk.

Typically, the administered dose is not expected to have any therapeutic or toxic effect but is high enough to allow measurement of drug concentration using ultra-sensitive analytical methods.

Step 1: Define the Study Objectives

Before protocol development, clearly define what you want to learn from the study:

• Does the drug reach systemic circulation?
• What is the absorption, half-life, and clearance profile?
• Can we confirm target engagement via biomarkers?
• Which compound among candidates should be advanced to Phase 1?

Clear objectives guide every design decision—from sampling schedules to bioanalytical assay selection.

Step 2: Determine the Microdose

According to regulatory definitions:

• A microdose is less than 1/100th of the pharmacologically active dose
• It should not exceed 100 micrograms for small molecules
• For biologics, the dose should not exceed 1/100th of the No Observed Adverse Effect Level (NOAEL)

Use available preclinical PK/PD data, allometric scaling, and in silico models to estimate a safe and detectable microdose.

Step 3: Choose the Route of Administration

The route should match the intended clinical use to ensure relevance. Common options include:

• Oral (tablets, capsules)
• Intravenous (IV)
• Subcutaneous or inhalation (for biologics or novel delivery systems)

Ensure formulation development is optimized for the low dose being administered.

Step 4: Select Analytical Methods for Detection

Due to the ultra-low drug concentrations, microdosing studies require highly sensitive and validated analytical techniques, such as:

• LC-MS/MS (Liquid Chromatography-Mass Spectrometry)
• Accelerator Mass Spectrometry (AMS) – capable of detecting 1 part per trillion
• PET Imaging – for tissue distribution using radiolabeled drugs

Validation should meet regulatory requirements for limit of detection (LOD), accuracy, and reproducibility.

Step 5: Design the Study Protocol

Components of a microdosing study protocol include:

Sample Size

• Typically 6 to 15 subjects per study
• May include crossover or parallel group design

Inclusion Criteria

• Healthy volunteers for general PK studies
• Patients in case of tissue-targeted oncology trials

Dosing Schedule

• Single-dose administration
• Sample collection at multiple time points: pre-dose and post-dose (e.g., 0.5h, 1h, 2h, 4h, 8h, 24h)

Endpoints

• Cmax, Tmax, AUC, half-life
• Target engagement using biomarkers or imaging

Monitoring

Although the doses are sub-therapeutic, monitor for unexpected adverse events and report them as per protocol.

Step 6: Ensure Regulatory and Ethical Compliance

Microdosing studies fall under Exploratory INDs (U.S.), Scientific Advice (EMA), or Phase 0 Guidance (India, Japan).

Submission must include:

• Preclinical single-dose tox data (1 species, GLP compliant)
• Assay validation reports
• Investigator Brochure (IB) and informed consent forms
• Ethics Committee / IRB approvals

Ensure compliance with ICH M3(R2), OECD GLP, and respective national health authorities.

Step 7: Data Collection and Analysis

Use validated tools and software for non-compartmental analysis (NCA) or model-based PK/PD analysis. Important parameters include:

• AUC – extent of absorption
• Cmax and Tmax – peak concentration and time
• Half-life (t½) – duration in circulation
• Bioavailability (if IV and oral data are available)

Biomarker or imaging endpoints should be analyzed for evidence of biological activity or distribution.

Case Example: Microdosing in CNS Drug Development

A CNS-targeted compound was microdosed (100 μg) in 10 healthy volunteers. Serial blood sampling and PET imaging confirmed blood-brain barrier penetration and receptor binding within 4 hours of administration. Based on this, the compound advanced confidently into Phase 1 trials.

Common Pitfalls to Avoid

• Assuming microdose PK is always predictive of full-dose PK (may not apply for saturable kinetics)
• Poor assay sensitivity leading to non-detectable results
• Neglecting formulation stability at low doses
• Inadequate documentation for regulatory approval

Summary for Clinical Research Students

Designing a microdosing study requires interdisciplinary expertise—from formulation science and bioanalytics to clinical protocol development and regulatory strategy. As a student or aspiring professional in clinical research, regulatory affairs, or pharmacology, understanding these design elements will help you contribute effectively to early-phase drug development.

Microdosing studies are a powerful tool in modern clinical science—if designed right, they can save time, money, and guide smarter development decisions.

Ethics and Safety in Phase 0 Trials: What Every Researcher Should Know

Introduction: Ethics at the Heart of Human Research

Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must adhere to the highest ethical and safety standards. The fact that Phase 0 studies may offer no direct benefit to the subject makes ethical oversight even more critical.

This tutorial covers the ethical principles, safety measures, and regulatory guidelines that must be followed to protect human subjects in Phase 0 clinical research.

Key Ethical Principles in Phase 0 Trials

Ethical conduct in Phase 0 trials is guided by globally accepted principles:

• Respect for persons – Informed consent and voluntary participation
• Beneficence – Maximize benefit, minimize harm (even if indirect)
• Justice – Fair subject selection and distribution of burden

These principles are codified in the Declaration of Helsinki, ICH-GCP (E6), and national regulations like Schedule Y (India).

Informed Consent in Phase 0 Trials

Participants must be given complete, clear, and accurate information about:

• The investigational nature of the drug
• The fact that no therapeutic benefit is expected
• Any potential risks, even if minimal
• Study procedures and duration
• Right to withdraw at any time

The Informed Consent Form (ICF) must be reviewed and approved by an Ethics Committee or Institutional Review Board (IRB).

Safety Considerations in Microdosing

Although doses are extremely low (usually ≤100 μg), safety remains a priority. Phase 0 trials include:

• Rigorous preclinical evaluation, including single-dose toxicity
• Monitoring of vital signs and adverse events
• Emergency response plans at the clinical site
• Stopping rules defined in the study protocol

Drugs used in microdosing must be free from genotoxic or carcinogenic concerns at projected exposure levels.

Ethical Justification of No Therapeutic Benefit

Phase 0 trials are conducted to generate early PK/PD data, not to provide treatment. Ethical justification depends on:

• Scientific validity and social value of the research
• Minimized risk to participants
• Transparent communication and voluntary consent

Most Phase 0 trials involve healthy volunteers, but in areas like oncology, terminally ill patients may be enrolled for tissue-targeted assessments. Additional ethical considerations apply in such cases.

Regulatory Oversight and Ethical Approvals

Ethical and regulatory oversight ensures compliance with human subject protection standards. Mandatory approvals include:

• Ethics Committee or IRB approval
• Regulatory authority clearance under exploratory IND (FDA), scientific advice (EMA), or CTA (CDSCO)
• Registration of the trial on clinical trial registries such as ClinicalTrials.gov or CTRI

Protocols must include risk management plans, consent templates, subject insurance details, and investigator training documentation.

Risk Minimization in Study Design

Strategies to minimize risk include:

• Careful dose selection based on NOAEL and allometric scaling
• Short study duration (1–7 days)
• Strict inclusion/exclusion criteria
• On-site medical monitoring and emergency support

Stopping rules should allow immediate suspension if adverse reactions occur—even if rare.

Compensation and Volunteer Protection

Participants in Phase 0 trials must be fairly compensated for:

• Time and inconvenience
• Travel and follow-up requirements
• Potential risks (including injury or hospitalization coverage)

In India, compensation is governed under GSR 889(E) and associated Schedule Y amendments. Global sponsors must align with local compensation laws and ethical standards.

Case Example: Ethics in Oncology Phase 0 Trial

A Phase 0 PET imaging study in advanced-stage cancer patients involved microdose administration of a novel radiotracer. Ethics committee approval emphasized:

• No therapeutic intent clearly disclosed
• Minimal added risk to already-ongoing imaging protocol
• Comprehensive consent and psychological counseling offered

The study yielded early receptor binding data and was considered ethically justified and scientifically valuable.

Summary for Clinical Research Students

Ethics is the foundation of all human research—including early-phase trials like Phase 0. As a student or emerging professional in clinical research, regulatory affairs, or pharmacovigilance, you must understand how to protect participants, even in low-risk studies. Phase 0 offers minimal clinical benefit but maximal learning—only if ethics and safety are integrated into every step.

When conducted ethically, Phase 0 trials are not just regulatory tools—they are symbols of research integrity and participant respect.

Step-by-Step Guide to Regulatory Submissions for Phase 0 Clinical Trials

Introduction: Regulatory Oversight in Phase 0 Trials

Phase 0 trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human subjects are protected and the study is scientifically and ethically justified.

This tutorial walks you through the step-by-step process for submitting regulatory applications for Phase 0 studies in the U.S. (FDA), Europe (EMA), and India (CDSCO).

Step 1: Understand the Regulatory Pathway

The first step is identifying the regulatory framework applicable to Phase 0 (exploratory) trials:

• FDA (USA): Exploratory IND under the 2006 guidance
• EMA (EU): Scientific Advice + CTA under EU Clinical Trials Regulation
• CDSCO (India): Clinical Trial Application under Schedule Y (Pilot/Exploratory Studies)

Each authority requires specific preclinical data, documentation format, and submission procedures.

Step 2: Preclinical Requirements

Unlike full Phase 1 submissions, Phase 0 requires a limited but robust nonclinical data package:

• Single-dose toxicity data in one rodent species
• Genotoxicity screening (e.g., Ames test)
• Pharmacokinetic (ADME) data from animal models
• Safety pharmacology (optional if justified)

All studies must follow GLP (Good Laboratory Practice) standards.

Step 3: Prepare the Investigational Medicinal Product (IMP) Dossier

Include detailed chemistry, manufacturing, and control (CMC) data for the microdose formulation:

• Active Pharmaceutical Ingredient (API) specifications
• Formulation composition, dose strength, and stability
• Batch records and certificates of analysis
• Sterility/pyrogen data (for injectables)

Ensure that the manufacturing facility is GMP-certified or qualified for clinical material preparation.

Step 4: Draft the Clinical Trial Protocol

Your protocol should clearly outline:

• Study objectives and endpoints (e.g., PK, PD, imaging)
• Number of participants (typically 6–15)
• Dose (≤100 μg or 1/100th therapeutic dose)
• Route and schedule of administration
• Inclusion/exclusion criteria and safety monitoring

Include stopping rules and risk minimization strategies.

Step 5: Prepare the Investigator’s Brochure (IB)

This document summarizes all known information about the investigational product:

• Pharmacology, toxicology, and ADME profile
• CMC and formulation details
• Prior in vitro and animal study results

The IB must be current, referenced, and scientifically justified.

Step 6: Submit the Application Package

For FDA (USA)

• File an Exploratory IND to the Division of Microbiology or relevant therapeutic area
• Follow 21 CFR Part 312 structure: Module 1–5 (eCTD)
• Include cover letter, preclinical summary, protocol, and IB

For EMA (EU)

• Apply for Scientific Advice if exploratory use of microdose
• Submit Clinical Trial Application (CTA) to the EU Portal
• Follow ICH CTD format and country-specific language/translations

For CDSCO (India)

• Prepare the Form CT-04 and Form CT-06 for trial permission
• Submit through SUGAM portal or hard copy with CD format
• Include preclinical dossier, protocol, IB, ethics approvals, and insurance details

Step 7: Ethics Committee (EC/IRB) Approval

Simultaneously, submit the protocol and informed consent documents to:

• IRB (Institutional Review Board) in the U.S.
• REC (Research Ethics Committee) in the EU
• IEC (Institutional Ethics Committee) in India (registered with CDSCO)

Include participant protection plan, ICF template, and risk communication strategy.

Step 8: Register the Trial

Before first enrollment, ensure registration on recognized platforms:

• ClinicalTrials.gov (U.S.)
• EudraCT or EU-CTR (EU)
• CTRI – Clinical Trials Registry India

Include brief summary, endpoints, sponsor details, and regulatory approval reference numbers.

Step 9: Site Readiness and Investigator Training

Ensure the trial site is GCP-compliant and ready with:

• Trained investigators and backup medical staff
• Emergency equipment and SOPs in place
• Drug accountability and documentation systems

Investigators must be trained on the investigational product, protocol, and consent process.

Step 10: Await Regulatory Authorization and Begin Trial

Typical timelines for approval:

• FDA: 30 days (if no clinical hold is issued)
• EMA: Up to 60 days (varies by country and central review)
• CDSCO: 60–90 days depending on dossier completeness

Begin trial only after receiving both regulatory and ethics approvals.

Summary for Clinical Research Students

Phase 0 regulatory submissions may be lighter than full-scale trials, but they still demand rigor, structure, and accountability. As a student or professional in regulatory affairs, clinical operations, or early-phase development, learning how to prepare a strong submission equips you for a strategic role in bringing therapies to the clinic—faster and more ethically.

By following these 10 steps, you’ll ensure your Phase 0 trial is compliant, efficient, and ready for first-in-human research.

Combining Phase 0 and Adaptive Phase 1 Trials: A Seamless Early Development Strategy

Introduction

Phase 0 trials provide early human pharmacokinetic and target engagement data. Phase 1 trials explore safety and dose tolerance. Combining these phases into a seamless development strategy using adaptive trial designs offers speed, efficiency, and data continuity. This approach is especially valuable for high-risk, high-reward programs such as oncology, CNS, or rare disease pipelines.

What is an Adaptive Phase 1 Trial?

An adaptive Phase 1 trial allows for modifications to key parameters—like dose level, cohort size, or schedule—based on interim data. Unlike fixed designs, adaptive trials respond dynamically to what’s being learned in real time.

By integrating Phase 0 data into an adaptive Phase 1 framework, developers can:

• Shorten timelines between studies
• Use human PK data to guide dose escalation
• Reduce exposure to subtherapeutic or unsafe doses

How the Integration Works

1. Conduct Phase 0 as a Lead-In

• Run a microdose study with ≤100 µg of drug
• Collect human PK and target binding data
• Model dose-exposure curves using PBPK simulation

2. Transition Directly into Adaptive Phase 1

• Design Phase 1 to adapt based on Phase 0 results
• Modify dose escalation scheme or starting dose if needed
• Optionally embed a ‘sentinel’ dosing strategy for safety

3. Use Combined Data for Dose Selection

• Define Minimum Anticipated Biological Effect Level (MABEL)
• Integrate biomarker response or imaging data
• Confirm target engagement before dose escalation

Design Options

Design A: Seamless Protocol

Single protocol includes a microdose cohort followed by adaptive dose escalation. Requires pre-approval of both stages by ethics and regulators.

Design B: Bridged Design

Separate protocols but use common investigator sites and teams. Phase 0 data is used to refine the Phase 1 protocol and submitted as an amendment.

Regulatory Considerations

• FDA: Allows exploratory INDs to transition into traditional INDs via amendments
• EMA: Supports integrated protocols under Clinical Trials Regulation with risk mitigation
• CDSCO: Requires protocol separation but permits transition with approval

Early engagement through pre-IND or Scientific Advice meetings is essential.

Benefits of Seamless Transition

• Accelerated time to first therapeutic dose
• Early human data reduces uncertainty in dose escalation
• Integrated safety monitoring from microdose through therapeutic range
• Cost-efficiency through shared infrastructure and CRO partners

Operational Tips for Execution

• Ensure assay sensitivity can cover both microdose and therapeutic levels
• Use cross-trained site staff to manage both study parts smoothly
• Keep SOPs aligned and approved for both stages from the outset
• Document data integration plan in clinical development plan (CDP)

Example: Seamless Oncology Early Development

A biotech company conducting a microdose PET imaging study transitioned immediately into an adaptive Phase 1 using the same site and investigators. Human PK and tumor uptake data informed the initial dose and escalation speed. The approach saved 4 months and significantly improved sponsor-investigator collaboration and decision-making.

Challenges and How to Manage Them

• Protocol complexity: Use modular designs and clear progression criteria
• Ethical committee approvals: Justify low risk in Phase 0 and transitional design
• Operational readiness: Coordinate CROs and clinical sites for immediate transition

Conclusion

Combining Phase 0 and adaptive Phase 1 trials is a forward-thinking strategy for data-driven, time-efficient drug development. With the right planning, modeling support, and regulatory engagement, it transforms the development timeline without compromising safety or data quality—turning exploratory trials into a springboard for success.